67 related articles for article (PubMed ID: 22686561)
1. Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies.
Martelli AM; Chiarini F; Evangelisti C; Ognibene A; Bressanin D; Billi AM; Manzoli L; Cappellini A; McCubrey JA
Expert Opin Ther Targets; 2012 Jul; 16(7):729-42. PubMed ID: 22686561
[TBL] [Abstract][Full Text] [Related]
2. The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator.
Faubert B; Vincent EE; Poffenberger MC; Jones RG
Cancer Lett; 2015 Jan; 356(2 Pt A):165-70. PubMed ID: 24486219
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer.
Zhang M; Yang H; Fu T; Meng M; Feng Y; Qu C; Li Z; Xing X; Li W; Ye M; Li S; Bu Z; Jia S
Mol Oncol; 2023 Sep; 17(9):1930-1942. PubMed ID: 37356061
[TBL] [Abstract][Full Text] [Related]
4. RAS-targeted cancer therapy: Advances in drugging specific mutations.
Liu C; Ye D; Yang H; Chen X; Su Z; Li X; Ding M; Liu Y
MedComm (2020); 2023 Jun; 4(3):e285. PubMed ID: 37250144
[TBL] [Abstract][Full Text] [Related]
5. Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review.
Zhang Y; Zhou F; Guan J; Zhou L; Chen B
Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830619
[TBL] [Abstract][Full Text] [Related]
6. Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors.
Matheson CJ; Casalvieri KA; Backos DS; Minhajuddin M; Jordan CT; Reigan P
Eur J Med Chem; 2020 Jul; 197():112316. PubMed ID: 32334266
[TBL] [Abstract][Full Text] [Related]
7. Targeting Metabolic Reprogramming in Acute Myeloid Leukemia.
Castro I; Sampaio-Marques B; Ludovico P
Cells; 2019 Aug; 8(9):. PubMed ID: 31450562
[TBL] [Abstract][Full Text] [Related]
8. LKB1 suppresses androgen synthesis in a mouse model of hyperandrogenism via IGF-1 signaling.
Xu Y; Gao Y; Huang Z; Zheng Y; Teng W; Zheng D; Zheng X
FEBS Open Bio; 2019 Oct; 9(10):1817-1825. PubMed ID: 31433577
[TBL] [Abstract][Full Text] [Related]
9. A Pyrazolo[3,4-
Laurenzana I; Caivano A; La Rocca F; Trino S; De Luca L; D'Alessio F; Schenone S; Falco G; Botta M; Del Vecchio L; Musto P
Front Pharmacol; 2016; 7():416. PubMed ID: 27872592
[TBL] [Abstract][Full Text] [Related]
10. Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport.
Velez J; Pan R; Lee JT; Enciso L; Suarez M; Duque JE; Jaramillo D; Lopez C; Morales L; Bornmann W; Konopleva M; Krystal G; Andreeff M; Samudio I
Oncotarget; 2016 Aug; 7(32):51435-51449. PubMed ID: 27283492
[TBL] [Abstract][Full Text] [Related]
11. Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders.
Evangelisti C; Cenni V; Lattanzi G
Br J Clin Pharmacol; 2016 Nov; 82(5):1229-1244. PubMed ID: 26952863
[TBL] [Abstract][Full Text] [Related]
12. Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.
Fernandes Â; Azevedo MM; Pereira O; Sampaio-Marques B; Paiva A; Correia-Neves M; Castro I; Ludovico P
Oncotarget; 2015 Oct; 6(31):31428-40. PubMed ID: 25537507
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Davis NM; Sokolosky M; Stadelman K; Abrams SL; Libra M; Candido S; Nicoletti F; Polesel J; Maestro R; D'Assoro A; Drobot L; Rakus D; Gizak A; Laidler P; Dulińska-Litewka J; Basecke J; Mijatovic S; Maksimovic-Ivanic D; Montalto G; Cervello M; Fitzgerald TL; Demidenko Z; Martelli AM; Cocco L; Steelman LS; McCubrey JA
Oncotarget; 2014 Jul; 5(13):4603-50. PubMed ID: 25051360
[TBL] [Abstract][Full Text] [Related]
14. GSK-3 as potential target for therapeutic intervention in cancer.
McCubrey JA; Steelman LS; Bertrand FE; Davis NM; Sokolosky M; Abrams SL; Montalto G; D'Assoro AB; Libra M; Nicoletti F; Maestro R; Basecke J; Rakus D; Gizak A; Demidenko ZN; Cocco L; Martelli AM; Cervello M
Oncotarget; 2014 May; 5(10):2881-911. PubMed ID: 24931005
[TBL] [Abstract][Full Text] [Related]
15. Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation.
Sui X; Xu Y; Yang J; Fang Y; Lou H; Han W; Zhang M; Chen W; Wang K; Li D; Jin W; Lou F; Zheng Y; Hu H; Gong L; Zhou X; Pan Q; Pan H; Wang X; He C
PLoS One; 2014; 9(5):e97781. PubMed ID: 24849329
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic death.
Bosnjak M; Ristic B; Arsikin K; Mircic A; Suzin-Zivkovic V; Perovic V; Bogdanovic A; Paunovic V; Markovic I; Bumbasirevic V; Trajkovic V; Harhaji-Trajkovic L
PLoS One; 2014; 9(4):e94374. PubMed ID: 24714637
[TBL] [Abstract][Full Text] [Related]
17. Chemical metabolic inhibitors for the treatment of blood-borne cancers.
Villalba M; Lopez-Royuela N; Krzywinska E; Rathore MG; Hipskind RA; Haouas H; Allende-Vega N
Anticancer Agents Med Chem; 2014 Feb; 14(2):223-32. PubMed ID: 24237221
[TBL] [Abstract][Full Text] [Related]
18. Integration of Different "-omics" Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia Cells.
Wiench B; Chen YR; Paulsen M; Hamm R; Schröder S; Yang NS; Efferth T
Evid Based Complement Alternat Med; 2013; 2013():818709. PubMed ID: 23861714
[TBL] [Abstract][Full Text] [Related]
19. Advances in targeting signal transduction pathways.
McCubrey JA; Steelman LS; Chappell WH; Sun L; Davis NM; Abrams SL; Franklin RA; Cocco L; Evangelisti C; Chiarini F; Martelli AM; Libra M; Candido S; Ligresti G; Malaponte G; Mazzarino MC; Fagone P; Donia M; Nicoletti F; Polesel J; Talamini R; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Michele M; Tafuri A; Dulińska-Litewka J; Laidler P; D'Assoro AB; Drobot L; Umezawa D; Montalto G; Cervello M; Demidenko ZN
Oncotarget; 2012 Dec; 3(12):1505-21. PubMed ID: 23455493
[TBL] [Abstract][Full Text] [Related]
20. Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65.
Bravo-Cuellar A; Hernández-Flores G; Lerma-Díaz JM; Domínguez-Rodríguez JR; Jave-Suárez LF; De Célis-Carrillo R; Aguilar-Lemarroy A; Gómez-Lomeli P; Ortiz-Lazareno PC
J Biomed Sci; 2013 Feb; 20(1):13. PubMed ID: 23445492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
